[{"id":"11de6afa-6e5b-4175-86c0-84377656d55c","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=54e2ba3069454692a3c1d22ffefdebd1","created_at":"2026-06-27T01:57:37.527Z","updated_at":"2026-06-27T01:57:37.527Z","phase":"Phase 3","brief_title":"Phase III study of MK-2870 in combination with pembrolizumab as first-line treatment for PD-L1-high expressing non-small cell lung cancer","source_id_and_acronym":"CTR20241031","lead_sponsor":"Merck R\u0026D (China) Co., Ltd.","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR L858R • ALK rearrangement • ALK translocation","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR L858R • ALK rearrangement • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/26/2024","start_date":" 06/26/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"577ff985-2f44-4752-9b4d-5d678b307277","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=576b9fdb439b4f04846f68c8d7f5d177","created_at":"2026-06-27T02:07:46.586Z","updated_at":"2026-06-27T02:07:46.586Z","phase":"Phase 3","brief_title":"Comparison of MK-2870 with platinum-based drugs and pemetrexed in patients with advanced EGFR m NSCLC who had received TKI therapy.","source_id_and_acronym":"CTR20242421","lead_sponsor":"Merck R\u0026D (China) Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Jiataile (sacituzumab tirumotecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 93","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"59598730-aa55-45cc-880c-a630868ca447","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=bea4a22d7c234bb49101470d59dab74a","created_at":"2026-06-27T02:19:29.947Z","updated_at":"2026-06-27T02:19:29.947Z","phase":"Phase 1","brief_title":"A phase Ib dose-escalation and dose-expansion study evaluating the safety, pharmacokinetics, and antitumor activity of vortexinib in patients with advanced or metastatic non-small cell lung cancer harboring EGFR or HER2 activating mutations.","source_id_and_acronym":"CTR20231537","lead_sponsor":"Shanghai Allis Pharmaceutical Technology Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • EGFR T790M • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • EGFR T790M • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ivesa (firmonertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"722e6757-2b92-4111-8537-f4c356d23347","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=11f7b2861f324796a9234d50cde5f463","created_at":"2026-06-27T02:00:11.721Z","updated_at":"2026-06-27T02:00:11.721Z","phase":"Phase 2","brief_title":"Evaluate the efficacy and safety of osimertinib before and during maintenance therapy in patients with stage III unresectable non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations.","source_id_and_acronym":"CTR20241401","lead_sponsor":"AstraZeneca AB / AstraZeneca Investment (China) Co., Ltd.","biomarkers":" CD4","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/03/2024","start_date":" 07/03/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"744c7d84-9070-4812-911b-014a6e6ca41d","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=bdbc5cb0fb4947c6b346bdebe3197e29","created_at":"2026-06-27T02:17:05.308Z","updated_at":"2026-06-27T02:17:05.308Z","phase":"Phase 1/2","brief_title":"A Phase Ib/II clinical study of the safety and efficacy of RC108 in combination with voreminib or in combination with voreminib and toripalimab in advanced NSCLC that has failed treatment with MET-expressing EGFR-TKIs.","source_id_and_acronym":"CTR20231178","lead_sponsor":"Rongchang Biopharmaceutical (Yantai) Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR G719X • EGFR S768I • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi)"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/07/2023","start_date":" 09/07/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"8147451c-7d54-46c1-864b-e687b200f7ea","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=c1f3d54c123e42bdb086bf36dbddd335","created_at":"2026-06-27T02:03:08.268Z","updated_at":"2026-06-27T02:03:08.268Z","phase":"Phase 2","brief_title":"An open-label, multicenter phase II clinical trial evaluating the efficacy and safety of beritinib in combination with PLB1004 as first-line treatment for patients with EGFR-mutant and MET-abnormal locally advanced or metastatic non-small cell lung cancer.","source_id_and_acronym":"CTR20241781","lead_sponsor":"Beijing Anshi Biotechnology Co., Ltd. / Kairui Life Science Technology (Tianjin) Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET overexpression • MET mutation • EGFR L858R + EGFR exon 19 deletion","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET overexpression • MET mutation • EGFR L858R + EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • andamertinib (PLB1004)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/07/2024","start_date":" 08/07/2024","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"8ba4b669-1019-40e4-99d4-da28f0cb5f1f","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=c00b248c33804fc181b30d568c374951","created_at":"2026-06-27T02:19:57.205Z","updated_at":"2026-06-27T02:19:57.205Z","phase":"Phase 1/2","brief_title":"Evaluating the safety and efficacy of beritinib in combination with PLB1004 in patients with locally advanced or metastatic non-small cell lung cancer.","source_id_and_acronym":"CTR20231603","lead_sponsor":"Beijing Anshi Biotechnology Co., Ltd.","biomarkers":" MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • MET overexpression • MET mutation • EGFR L858R + EGFR exon 19 deletion","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • MET overexpression • MET mutation • EGFR L858R + EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e andamertinib (PLB1004)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"c66e707c-30c1-4505-83b6-e61bfa1de66a","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=daad049b3cdc49a88f2c6fda38ef4de5","created_at":"2026-06-27T02:26:50.854Z","updated_at":"2026-06-27T02:26:50.854Z","phase":"Phase 1","brief_title":"A Phase Ib/II clinical trial evaluating the efficacy and safety of LMV-12 (HE003) tablets in the treatment of locally advanced or metastatic malignant solid tumors.","source_id_and_acronym":"CTR20232499","lead_sponsor":"Nanchang Hongyi Pharmaceutical Co., Ltd. / Nanchang Hongyi Technology Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • RET fusion • EGFR exon 20 insertion • MET exon 14 mutation • MET mutation • EGFR exon 20 mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • RET fusion • EGFR exon 20 insertion • MET exon 14 mutation • MET mutation • EGFR exon 20 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/14/2023","start_date":" 09/14/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"d592c496-6138-4ba1-a862-c869cebf5eca","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=90028ea2a84544bb90712cedd8a029d8","created_at":"2026-06-27T02:12:03.609Z","updated_at":"2026-06-27T02:12:03.609Z","phase":"Phase 3","brief_title":"Subcutaneous administration of MK-3475A combined with chemotherapy versus intravenous administration of pembrolizumab combined with chemotherapy for the treatment of previously untreated metastatic non-small cell lung cancer.","source_id_and_acronym":"CTR20231113","lead_sponsor":"Merck Sharp \u0026 Dohme LLC, a subsidiary of Merck \u0026 Co., Inc. / Baxter Oncology GmbH (China) Co., Ltd.","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • ALK rearrangement","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • pemetrexed • atorvastatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"dd98720a-fc4b-424b-b911-db8b262665d0","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=355e4ed9d3d8491fa9ad6a4227a07251","created_at":"2026-06-27T02:11:54.102Z","updated_at":"2026-06-27T02:11:54.102Z","phase":"Phase 2","brief_title":"A Phase II clinical trial of DZD9008 in combination with AZD4205 in NSCLC patients with EGFR mutations who have failed standard therapy.","source_id_and_acronym":"CTR20231074","lead_sponsor":"Dizhe (Jiangsu) Pharmaceutical Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zegfrovy (sunvozertinib) • golidocitinib (DZD4205)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-26"},{"id":"1aade406-53bb-40f8-ab49-0f81c7fd5f30","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=8fddb07497854d4aa391f1781001716c","created_at":"2026-06-27T02:44:54.873Z","updated_at":"2026-06-27T02:44:54.873Z","phase":"Phase 3","brief_title":"A study comparing the combination of MK-7684 and pembrolizumab (MK-7684A) with chemotherapy as first-line treatment for metastatic non-small cell lung cancer with pembrolizumab alone.","source_id_and_acronym":"CTR20221804","lead_sponsor":"Merck Sharp \u0026 Dohme Corp., a subsidiary of Merck \u0026 Co., Inc. / MSD Ireland (Carlow) Co., Ltd.","biomarkers":" EGFR • PD-L1 • KRAS • ALK • ROS1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • EGFR L858R • ALK rearrangement","tags":["EGFR • PD-L1 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • EGFR L858R • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • pemetrexed • vibostolimab/pembrolizumab (MK-7684A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 10/20/2022","start_date":" 10/20/2022","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"22003c94-ab94-4f49-9a77-47c51cd51f72","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=79e3421a43f6488b90380373775648b6","created_at":"2026-06-27T02:52:57.526Z","updated_at":"2026-06-27T02:52:57.526Z","phase":"Phase 2","brief_title":"Sutertinib Phase IIc Clinical Trial","source_id_and_acronym":"CTR20223110","lead_sponsor":"Jiangsu Suzhong Pharmaceutical Group Co., Ltd. / Jiangsu Maidu Pharmaceutical R\u0026D Co., Ltd.","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR positive","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/03/2023","start_date":" 04/03/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"4ebb1da2-fbcd-462d-933b-b33596cdaf19","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=ab490e1c095849cab274aa152224d400","created_at":"2026-06-27T03:07:24.976Z","updated_at":"2026-06-27T03:07:24.976Z","phase":"Phase 1","brief_title":"An open-label phase I study evaluating the safety, tolerability, pharmacokinetics, and antitumor activity of FWD1509 MsOH in patients with advanced non-small cell lung cancer.","source_id_and_acronym":"CTR20211750","lead_sponsor":"Shenzhen Fuwo Pharmaceutical Co., Ltd.","biomarkers":" EGFR • HER-2","pipe":" | ","alterations":" EGFR mutation • HER-2 amplification • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation","tags":["EGFR • HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 amplification • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • HER-2 exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FWD1509"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 09/29/2021","start_date":" 09/29/2021","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"b9c78742-0226-4805-8cc3-43d5bc7d68f1","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=6bce76d8fbf745eabf430a1d10c455a1","created_at":"2026-06-27T02:54:42.002Z","updated_at":"2026-06-27T02:54:42.002Z","phase":"Phase 3","brief_title":"Comparison of MK-3475 monotherapy versus combination therapy with goxatozumab and MK-3475 in metastatic NSCLC patients with PD-L1 TPS ≥ 50%.","source_id_and_acronym":"CTR20223405","lead_sponsor":"Merck Sharp \u0026 Dohme Corp. / MSD Research \u0026 Development (China) Co., Ltd. / MSD Ireland (Carlow)","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR L858R • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR L858R • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 03/30/2023","start_date":" 03/30/2023","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"bfb52d9c-8961-431e-9d8a-0d922fbb148d","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=d2ebffa9585d44a18ae7e723d4efafe6","created_at":"2026-06-27T02:52:50.411Z","updated_at":"2026-06-27T02:52:50.411Z","phase":"Phase 3","brief_title":"A study on the efficacy and safety of SH-1028 tablets versus placebo as adjuvant therapy for stage II-IIIB non-small cell lung cancer with epidermal growth factor receptor sensitive mutations.","source_id_and_acronym":"CTR20223093","lead_sponsor":"Nanjing Shenghe Pharmaceutical Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sanrisso (rilertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 242","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"c48ada99-9d16-41a0-8fc3-d05f7296beaf","acronym":"","url":"https://clinicaltrials.gov/study/NCT07669051","created_at":"2026-06-27T02:22:18.221Z","updated_at":"2026-06-27T02:22:18.221Z","phase":"Phase 2","brief_title":"A Phase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer With Gradual or Potential Progression After EGFR-TKIs Treatment","source_id_and_acronym":"NCT07669051","lead_sponsor":"Shandong Cancer Hospital and Institute","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Idafang (ivonescimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2029","study_completion_date":" 01/01/2029","last_update_posted":"2026-06-25"},{"id":"c634ba6f-8d40-48be-8f3d-a3bddd7fa450","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=8e82de910cf54d99bbad8cfa2ef1799c","created_at":"2026-06-27T03:02:22.511Z","updated_at":"2026-06-27T03:02:22.511Z","phase":"Phase 3","brief_title":"A phase III clinical trial of amitinib in combination with platinum-based doublet chemotherapy versus amitinib monotherapy for EGFR-sensitive mutation NSCLC.","source_id_and_acronym":"CTR20211135","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Group Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Ameile (aumolertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 624","initiation":"Initiation: 08/11/2021","start_date":" 08/11/2021","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-25"},{"id":"03aa6c66-3dc5-4e29-addc-170316a9073f","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=ab1e75f26eae4c4fb6f62df6e0a70746","created_at":"2026-06-27T03:35:01.695Z","updated_at":"2026-06-27T03:35:01.695Z","phase":"Phase 3","brief_title":"Evaluating the efficacy and safety of SCT510 in the treatment of non-small cell lung cancer.","source_id_and_acronym":"CTR20181634","lead_sponsor":"Shenzhou Cell Engineering Co., Ltd.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • EGFR G719X","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • EGFR G719X"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Completed","enrollment":" Enrollment 560","initiation":"Initiation: 03/29/2019","start_date":" 03/29/2019","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"0c5cafae-d8a5-4c04-bcc8-f82c30c49dda","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=b99bcc9ef5d4487aaf5dadc2de5abe6d","created_at":"2026-06-27T03:47:24.617Z","updated_at":"2026-06-27T03:47:24.617Z","phase":"Phase 1","brief_title":"A dose-finding study in subjects with advanced non-small cell lung cancer","source_id_and_acronym":"CTR20190589","lead_sponsor":"Janssen Research \u0026 Development, LLC / Janssen Pharmaceutica NV / Janssen Pharmaceutica NV, Fisher Clinical Services / Xi'an Janssen Pharmaceutical Co., Ltd.","biomarkers":" ALK • MET","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • ALK mutation • ALK wild-type • MET mutation • MET expression • EGFR exon 20 mutation","tags":["ALK • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • ALK mutation • ALK wild-type • MET mutation • MET expression • EGFR exon 20 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 04/23/2020","start_date":" 04/23/2020","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"0f16ff79-4102-46bb-9ca5-0c3dc33860a5","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=3744659576904033b42cc6983afd32d7","created_at":"2026-06-27T03:47:59.221Z","updated_at":"2026-06-27T03:47:59.221Z","phase":"Phase 2","brief_title":"Phase IIa Clinical Study of Sutertinib Maleate Capsules","source_id_and_acronym":"CTR20190681","lead_sponsor":"Jiangsu Suzhong Pharmaceutical Group Co., Ltd. / Jiangsu Maidu Pharmaceutical R\u0026D Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 07/15/2019","start_date":" 07/15/2019","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"16b27ebf-0ca2-4d9e-ae28-2f6229d181c6","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=89e0069ef6da446596e9f8c2835c444f","created_at":"2026-06-27T03:43:14.851Z","updated_at":"2026-06-27T03:43:14.851Z","phase":"Phase 3","brief_title":"Phase III trial of erflutinib mesylate as a first-line drug","source_id_and_acronym":"CTR20182519","lead_sponsor":"Shanghai Allis Pharmaceutical Technology Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gefitinib • Ivesa (firmonertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 358","initiation":"Initiation: 05/31/2019","start_date":" 05/31/2019","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"1a4ee4a9-477b-4a0f-a4ba-9bec8386d076","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=6aa29068e9e641f98b1981aca14d2a92","created_at":"2026-06-27T03:21:27.606Z","updated_at":"2026-06-27T03:21:27.606Z","phase":"Phase 3","brief_title":"A phase III clinical trial of ametinib mesylate or placebo in combination with chemotherapy as perioperative treatment for non-small cell lung cancer.","source_id_and_acronym":"CTR20201857","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Group Co., Ltd. / Shanghai Hansoh Biomedical Technology Co., Ltd.","biomarkers":" EGFR • KIT","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR positive","tags":["EGFR • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • pemetrexed • Ameile (aumolertinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 350","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"3082c5bd-6d89-40d0-8635-cc7ad4f4216b","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=95008a30b49e4beea58c33658c04847c","created_at":"2026-06-27T03:29:23.068Z","updated_at":"2026-06-27T03:29:23.068Z","phase":"Phase 3","brief_title":"A study on the efficacy and safety of ametinib mesylate versus placebo as adjuvant therapy for stage II-IIIB non-small cell lung cancer with epidermal growth factor receptor-sensitive mutations.","source_id_and_acronym":"CTR20202460","lead_sponsor":"Jiangsu Hansoh Pharmaceutical Group Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 192","initiation":"Initiation: 05/17/2021","start_date":" 05/17/2021","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"},{"id":"6803b809-c50d-4fd6-9fe6-703117882ea8","acronym":"","url":"https://www.chinadrugtrials.org.cn/clinicaltrials.searchlistdetail.dhtml?id=0d937865940b4449baf95698f9feb58b_p","created_at":"2026-06-27T03:48:08.717Z","updated_at":"2026-06-27T03:48:08.717Z","phase":"Phase 1","brief_title":"Phase I clinical trial of avitinib maleate capsules","source_id_and_acronym":"CTR20190705","lead_sponsor":"Hangzhou Aisen Pharmaceutical Research Co., Ltd. / Aisen Biotechnology (Hangzhou) Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fujovee (abivertinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2026-06-24"}]